Imbruvica and Decreased activity - a phase IV clinical study of FDA data

Summary:

Decreased activity is reported as a side effect among people who take Imbruvica (ibrutinib), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Xarelto, and have Chronic lymphocytic leukaemia.

The phase IV clinical study analyzes which people have Decreased activity when taking Imbruvica. It is created by eHealthMe based on reports of 69,938 people who have side effects when taking Imbruvica from the FDA, and is updated regularly.

What is Imbruvica?

Imbruvica has active ingredients of ibrutinib. It is often used in chronic lymphocytic leukemia (cll). eHealthMe is studying from 70,020 Imbruvica users. Check the latest studies of Imbruvica.

What is Decreased activity?

Decreased activity is found to be associated with 1,111 drugs and 1,329 conditions by eHealthMe. Check the latest studies of Decreased activity.

On Aug, 10, 2026

69,938 people reported to have side effects when taking Imbruvica.
Among them, 76 people (0.11%) have Decreased activity.

Could Imbruvica cause Decreased activity?

Among these 76 people:

How long have people been on Imbruvica when they have Decreased activity? *

What is the gender of people who have Decreased activity when taking Imbruvica? *

female: 34.67 %
male: 65.33 %

What is the age of people who have Decreased activity when taking Imbruvica? *

What are other drugs people take besides Imbruvica? *

What are other side effects people have besides Decreased activity? *

Fatigue (feeling of tiredness): 24 people, 31.58%
Emotional Disorder: 13 people, 17.11%
Memory Loss: 12 people, 15.79%
White Blood Cell Count Decreased: 10 people, 13.16%
Fall: 10 people, 13.16%
Diarrhea: 10 people, 13.16%
Depression: 9 people, 11.84%
White Blood Cell Count Increased: 8 people, 10.53%
Pneumonia: 8 people, 10.53%
Dizziness: 8 people, 10.53%

What are the existing conditions these people have? *

Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 52 people, 68.42%
Lymphocytic Leukaemia (a type of cancer in which the bone marrow makes too many lymphocytes): 8 people, 10.53%
Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 7 people, 9.21%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 6 people, 7.89%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 3 people, 3.95%
B-Cell Small Lymphocytic Lymphoma (blood cancer affecting b cells): 2 people, 2.63%
Chronic Lymphocytic Leukaemia Recurrent (repeated cancer of blood cells known as lymphocytes): 2 people, 2.63%
High Blood Pressure: 2 people, 2.63%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 2.63%
Neoplasm Malignant (cancer tumour): 2 people, 2.63%

* Approximation only. Some reports may have incomplete information.

Do you take Imbruvica and have Decreased activity?

- Check whether Decreased activity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Imbruvica:

Imbruvica (70,020 reports)

Browse all side effects of Imbruvica:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Decreased activity:

Decreased activity (1,111 drugs)

Browse all the conditions that are associated with Decreased activity:

Decreased activity (1,329 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ibrutinib (the active ingredients of Imbruvica) and Imbruvica (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.